Current Report Filing (8-k)
September 11 2017 - 4:52PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 11, 2017
Portola Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-35935
|
|
20-0216859
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
270 E. Grand Avenue
South San Francisco, California
|
|
94080
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (650)
246-7300
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of
this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On September 11, 2017, Portola Pharmaceuticals, Inc. (the
Company) updated its corporate presentation, which is attached as Exhibit 99.1 to this Current Report on Form
8-K
and is incorporated herein by reference. Representatives of the Company
will use the updated presentation from time to time at conferences and in meetings with investors.
An updated set of risk factors for the
Company is filed as Exhibit 99.2 to this Current Report on Form
8-K
and is incorporated herein by reference. This disclosure updates our publicly available risk factors, previously disclosed in Part II, Item
1A. Risk Factors in our Quarterly Report on Form
10-Q
for the quarter ended June 30, 2017.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Portola Pharmaceuticals, Inc.
|
Dated: September 11, 2017
|
|
|
|
|
By:
|
|
/s/ Mardi C. Dier
|
|
|
|
|
Mardi C. Dier
|
|
|
|
|
Executive Vice President and Chief Financial Officer
|
Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
From Apr 2023 to Apr 2024